This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Amryt Pharma 관리

관리 기준 확인 2/4

주요 정보

Joe Wiley

최고 경영자

US$1.7m

총 보상

CEO 급여 비율	43.4%
CEO 임기	8.3yrs
CEO 소유권	1.1%
경영진 평균 재임 기간	3.3yrs
이사회 평균 재임 기간	3.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Joe Wiley 의 보수는 Amryt Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2022	n/a	n/a	-US$790k
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$3m
Dec 31 2021	US$2m	US$747k	US$1m
Sep 30 2021	n/a	n/a	-US$88m
Jun 30 2021	n/a	n/a	-US$81m
Mar 31 2021	n/a	n/a	-US$92m
Dec 31 2020	US$2m	US$727k	-US$105m
Sep 30 2020	n/a	n/a	-US$87m
Jun 30 2020	n/a	n/a	-US$92m
Mar 31 2020	n/a	n/a	-US$87m
Dec 31 2019	US$1m	US$588k	-US$63m

보상 대 시장: Joe's total compensation ($USD1.72M) is above average for companies of similar size in the German market ($USD1.29M).

보상과 수익: Joe's compensation has increased whilst the company is unprofitable.

CEO

Joe Wiley (51 yo)

8.3yrs

테뉴어

US$1,720,000

보상

Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...

리더십 팀

이름	위치	테뉴어	보상	소유권
Joseph Wiley	CEO & Director	8.3yrs	US$1.72m	1.1% $ 9.4m
Rory Nealon	CFO, COO & Company Secretary	8.3yrs	US$939.00k	0.51% $ 4.4m
Elizabeth Jobes	Chief Compliance Officer	2.3yrs	데이터 없음	데이터 없음
John McEvoy	General Counsel	5.6yrs	데이터 없음	데이터 없음
Stephen Joyce	Head of Marketing & Head of APAC	4.3yrs	데이터 없음	데이터 없음
Julie Eastwood	Head of Human Resources	no data	데이터 없음	데이터 없음
Helen Phillips	Head of Medical Affairs	no data	데이터 없음	데이터 없음
Sheila Frame	President of Americas	2yrs	데이터 없음	데이터 없음
Tracy Cunningham	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Jordi Casals	President of EMEA Region	less than a year	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 3N9A's management team is considered experienced (3.3 years average tenure).

이사회 구성원

이름	위치	테뉴어	보상	소유권
Joseph Wiley	CEO & Director	7yrs	US$1.72m	1.1% $ 9.4m
Stephen Wills	Independent Non-Executive Director	3.6yrs	US$88.00k	0.023% $ 199.6k
Alain Munoz	Independent Non-Executive Director	3.6yrs	US$58.00k	0.0070% $ 59.9k
Patrick V. J. Vink	Independent Non-Executive Director	3.6yrs	US$60.00k	0.0078% $ 66.5k
Donald Stern	Independent Non-Executive Director	3.6yrs	US$80.00k	0% $ 0
Raymond Stafford	Independent Non-Executive Chairman of the Board	7yrs	US$88.00k	0.61% $ 5.2m
Roni Mamluk	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0
George Hampton	Independent Non-Executive Director	3.6yrs	US$65.00k	0.031% $ 266.1k
Raj Kannan	Independent Non-Executive Director	1.7yrs	US$20.00k	0% $ 0

3.6yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 3N9A's board of directors are considered experienced (3.6 years average tenure).

This company listing is no longer active

Amryt Pharma 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Recent updates

Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly

Amryt Pharma plc Re-Affirms Revenue Guidance for the Year 2022

Amryt Pharma plc to Report Q3, 2022 Results on Nov 03, 2022

Amryt Announces COMP Adopts Positive Opinion on Orphan Disease Designation for Mycapssa for Treatment of Acromegaly

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta (Metreleptin)

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez(R) in Great Britain

Amryt Pharma plc Provides Earnings Guidance for the Full Year 2022

Amryt Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa(R) (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt Announces European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

Amryt Presents Data for Mycapssa (Oral Octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa(R) (oral octreotide) at ENDO 2022

Amryt Pharma plc, Annual General Meeting, Jun 30, 2022

Amryt Pharma plc Announces New Patent for Mycapssa®

Amryt Pharma plc Reaffirms Revenue Guidance for Fiscal Year 2022

CHMP Adopts positive opinion for Filsuvez(R) for the treatment of Dystrophic and Junctional EB

Amryt Pharma plc to Report Q1, 2022 Results on May 04, 2022

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Amryt Announces Successful Bioavailability Study for Mycapssa® (Octreotide Capsules)

Amryt Receives Complete Response Letter from the U.S. Food and Drug Administration for Oleogel-S10 NDA

Amryt Announces Oleogel-S10 EMA Regulatory Update

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide)

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients

Amryt Pharma plc Provides Update on Regulatory Review Process for Oleogel-S1

Amryt Announces the Cancellation of Admission of Its Ordinary Shares to Trading on AIM

Amryt Pharma plc Revises Revenue Guidance for the Year 2021

Amryt Pharma plc Announces Earnings Guidance for the Fiscal Year 2021

Amryt Pharma plc completed the acquisition of Chiasma, Inc. from MPM Capital and others.

U.S. Food and Drug Administration Confirms Amryt’s New Drug Application for Oleogel-S10 Will Not Require an Advisory Committee Meeting

U.S. Food and Drug Administration Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

Amryt Pharma plc entered into an agreement to acquire Chiasma, Inc. from MPM Capital and others for approximately $290 million.

Amryt and Medison Pharma Canada Sign Distribution Agreement for Myalepta (Metreleptin) in Canada

Amryt Pharma plc to Report Q4, 2020 Results on Mar 04, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt Pharma plc Receives Reimbursement Approval from Nice for Myalepta in England and Wales

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (Lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta in Brazil

Amryt Pharma plc Raises Sales Guidance for the Full Year 2020

Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® in Epidermolysis Bullosa

Amryt Signs Distribution Agreement with Swixx BioPharma AG

Amryt and Swixx Sign Distribution Deal for Lojuxta

Amryt Pharma plc to Report Q3, 2020 Results on Nov 05, 2020

Amryt Pharma Intends to Cancel the Admission of the Ordinary Shares to Trading on the Euronext Growth Market

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령